124 related articles for article (PubMed ID: 37558007)
1. Remodeling of lipid landscape in high fat fed very-long chain acyl-CoA dehydrogenase null mice favors pro-arrhythmic polyunsaturated fatty acids and their downstream metabolites.
Lefort B; Gélinas R; Forest A; Bouchard B; Daneault C; Robillard Frayne I; Roy J; Oger C; Greffard K; Galano JM; Durand T; Labarthe F; Bilodeau JF; Ruiz M; Des Rosiers C
Biochim Biophys Acta Mol Basis Dis; 2023 Dec; 1869(8):166843. PubMed ID: 37558007
[TBL] [Abstract][Full Text] [Related]
2. Tissue-specific strategies of the very-long chain acyl-CoA dehydrogenase-deficient (VLCAD-/-) mouse to compensate a defective fatty acid β-oxidation.
Tucci S; Herebian D; Sturm M; Seibt A; Spiekerkoetter U
PLoS One; 2012; 7(9):e45429. PubMed ID: 23024820
[TBL] [Abstract][Full Text] [Related]
3. Cardiac tissue citric acid cycle intermediates in exercised very long-chain acyl-CoA dehydrogenase-deficient mice fed triheptanoin or medium-chain triglyceride.
Gaston G; Gangoiti JA; Winn S; Chan B; Barshop BA; Harding CO; Gillingham MB
J Inherit Metab Dis; 2020 Nov; 43(6):1232-1242. PubMed ID: 33448436
[TBL] [Abstract][Full Text] [Related]
4. Prolonged QT interval and lipid alterations beyond β-oxidation in very long-chain acyl-CoA dehydrogenase null mouse hearts.
Gélinas R; Thompson-Legault J; Bouchard B; Daneault C; Mansour A; Gillis MA; Charron G; Gavino V; Labarthe F; Des Rosiers C
Am J Physiol Heart Circ Physiol; 2011 Sep; 301(3):H813-23. PubMed ID: 21685264
[TBL] [Abstract][Full Text] [Related]
5. De novo fatty acid biosynthesis and elongation in very long-chain acyl-CoA dehydrogenase-deficient mice supplemented with odd or even medium-chain fatty acids.
Tucci S; Behringer S; Spiekerkoetter U
FEBS J; 2015 Nov; 282(21):4242-53. PubMed ID: 26284828
[TBL] [Abstract][Full Text] [Related]
6. Very long-chain acyl-CoA dehydrogenase (VLCAD-) deficiency-studies on treatment effects and long-term outcomes in mouse models.
Tucci S
J Inherit Metab Dis; 2017 May; 40(3):317-323. PubMed ID: 28247148
[TBL] [Abstract][Full Text] [Related]
7. Heptanoate Improves Compensatory Mechanism of Glucose Homeostasis in Mitochondrial Long-Chain Fatty Acid Oxidation Defect.
Nurjanah S; Gerding A; Vieira-Lara MA; Evers B; Langelaar-Makkinje M; Spiekerkoetter U; Bakker BM; Tucci S
Nutrients; 2023 Nov; 15(21):. PubMed ID: 37960342
[TBL] [Abstract][Full Text] [Related]
8. Fatty acid oxidation flux predicts the clinical severity of VLCAD deficiency.
Diekman EF; Ferdinandusse S; van der Pol L; Waterham HR; Ruiter JP; Ijlst L; Wanders RJ; Houten SM; Wijburg FA; Blank AC; Asselbergs FW; Houtkooper RH; Visser G
Genet Med; 2015 Dec; 17(12):989-94. PubMed ID: 25834949
[TBL] [Abstract][Full Text] [Related]
9. AAV9 gene replacement therapy for respiratory insufficiency in very-long chain acyl-CoA dehydrogenase deficiency.
Zieger M; Keeler AM; Flotte TR; ElMallah MK
J Inherit Metab Dis; 2019 Sep; 42(5):870-877. PubMed ID: 30993714
[TBL] [Abstract][Full Text] [Related]
10. Electrophysiological Abnormalities in VLCAD Deficient hiPSC-Cardiomyocytes Can Be Improved by Lowering Accumulation of Fatty Acid Oxidation Intermediates.
Knottnerus SJG; Mengarelli I; Wüst RCI; Baartscheer A; Bleeker JC; Coronel R; Ferdinandusse S; Guan K; IJlst L; Li W; Luo X; Portero VM; Ulbricht Y; Visser G; Wanders RJA; Wijburg FA; Verkerk AO; Houtkooper RH; Bezzina CR
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32276429
[TBL] [Abstract][Full Text] [Related]
11. Proposal for an individualized dietary strategy in patients with very long-chain acyl-CoA dehydrogenase deficiency.
Bleeker JC; Kok IL; Ferdinandusse S; de Vries M; Derks TGJ; Mulder MF; Williams M; Gozalbo ER; Bosch AM; van den Hurk DT; de Sain-van der Velden MGM; Waterham HR; Wijburg FA; Visser G
J Inherit Metab Dis; 2019 Jan; 42(1):159-168. PubMed ID: 30740737
[TBL] [Abstract][Full Text] [Related]
12. Molecular and cellular pathology of very-long-chain acyl-CoA dehydrogenase deficiency.
Schiff M; Mohsen AW; Karunanidhi A; McCracken E; Yeasted R; Vockley J
Mol Genet Metab; 2013 May; 109(1):21-7. PubMed ID: 23480858
[TBL] [Abstract][Full Text] [Related]
13. Gestational, pathologic and biochemical differences between very long-chain acyl-CoA dehydrogenase deficiency and long-chain acyl-CoA dehydrogenase deficiency in the mouse.
Cox KB; Hamm DA; Millington DS; Matern D; Vockley J; Rinaldo P; Pinkert CA; Rhead WJ; Lindsey JR; Wood PA
Hum Mol Genet; 2001 Sep; 10(19):2069-77. PubMed ID: 11590124
[TBL] [Abstract][Full Text] [Related]
14. Medium-chain triglycerides impair lipid metabolism and induce hepatic steatosis in very long-chain acyl-CoA dehydrogenase (VLCAD)-deficient mice.
Tucci S; Primassin S; Ter Veld F; Spiekerkoetter U
Mol Genet Metab; 2010 Sep; 101(1):40-7. PubMed ID: 20580297
[TBL] [Abstract][Full Text] [Related]
15. Food withdrawal lowers energy expenditure and induces inactivity in long-chain fatty acid oxidation-deficient mouse models.
Diekman EF; van Weeghel M; Wanders RJ; Visser G; Houten SM
FASEB J; 2014 Jul; 28(7):2891-900. PubMed ID: 24648546
[TBL] [Abstract][Full Text] [Related]
16. A heterozygous missense mutation in adolescent-onset very long-chain acyl-CoA dehydrogenase deficiency with exercise-induced rhabdomyolysis.
Hisahara S; Matsushita T; Furuyama H; Tajima G; Shigematsu Y; Imai T; Shimohama S
Tohoku J Exp Med; 2015 Apr; 235(4):305-10. PubMed ID: 25843429
[TBL] [Abstract][Full Text] [Related]
17. Development and pathomechanisms of cardiomyopathy in very long-chain acyl-CoA dehydrogenase deficient (VLCAD(-/-)) mice.
Tucci S; Flögel U; Hermann S; Sturm M; Schäfers M; Spiekerkoetter U
Biochim Biophys Acta; 2014 May; 1842(5):677-85. PubMed ID: 24530811
[TBL] [Abstract][Full Text] [Related]
18. The fate of medium-chain fatty acids in very long-chain acyl‑CoA dehydrogenase deficiency (VLCADD): A matter of sex?
Wehbe Z; Alatibi K; Jellusova J; Spiekerkoetter U; Tucci S
Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Nov; 1864(11):1591-1605. PubMed ID: 31394165
[TBL] [Abstract][Full Text] [Related]
19. Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders.
Djouadi F; Aubey F; Schlemmer D; Ruiter JP; Wanders RJ; Strauss AW; Bastin J
Hum Mol Genet; 2005 Sep; 14(18):2695-703. PubMed ID: 16115821
[TBL] [Abstract][Full Text] [Related]
20. Impact of newborn screening for very-long-chain acyl-CoA dehydrogenase deficiency on genetic, enzymatic, and clinical outcomes.
Bleeker JC; Kok IL; Ferdinandusse S; van der Pol WL; Cuppen I; Bosch AM; Langeveld M; Derks TGJ; Williams M; de Vries M; Mulder MF; Gozalbo ER; de Sain-van der Velden MGM; Rennings AJ; Schielen PJCI; Dekkers E; Houtkooper RH; Waterham HR; Pras-Raves ML; Wanders RJA; van Hasselt PM; Schoenmakers M; Wijburg FA; Visser G
J Inherit Metab Dis; 2019 May; 42(3):414-423. PubMed ID: 30761551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
